Personal Care Compositions and Methods for the Same

ABSTRACT

Personal care compositions and methods for treating or reducing skin irritation or skin inflammation. The personal care composition may include a carrier, one or more plant oils, and a cannabinoid source. The one or more plant oils and the cannabinoid source may each be present in an effective amount to treat or reduce skin irritation or skin inflammation. The method for treating or reducing skin irritation or skin inflammation may include contacting the personal care composition with skin, and optionally, decreasing the amount of IL-1α in or on the skin.

BACKGROUND

Personal care compositions may often incorporate beneficial componentsor benefit agents to impart benefits or properties to the compositions.For example, skincare compositions may often incorporate skin soothingagents to provide the composition with the ability to ameliorate,reduce, or treat skin irritation. While the incorporation of thesebenefit agents has exhibited efficacy in enhancing the respectiveproperties of the personal care compositions, the search for new benefitagents exhibiting improved benefits is ongoing.

What is needed, then, are personal care compositions incorporatingimproved benefit agents, and methods for the same.

BRIEF SUMMARY

This summary is intended merely to introduce a simplified summary ofsome aspects of one or more implementations of the present disclosure.Further areas of applicability of the present disclosure will becomeapparent from the detailed description provided hereinafter. Thissummary is not an extensive overview, nor is it intended to identify keyor critical elements of the present teachings, nor to delineate thescope of the disclosure. Rather, its purpose is merely to present one ormore concepts in simplified form as a prelude to the detaileddescription below.

The foregoing and/or other aspects and utilities embodied in the presentdisclosure may be achieved by providing a personal care compositionincluding a carrier, one or more plant oils, and a cannabinoid source.The one or more plant oils and the cannabinoid source may each bepresent in an effective amount to treat or reduce skin irritation orskin inflammation.

In at least one example, the one or more plant oils may include one ormore of the following: palm kernel oil, coconut oil, avocado oil, canolaoil, corn oil, cottonseed oil, olive oil, palm oil, high-oleic sunfloweroil, mid-oleic sunflower oil, sunflower oil, palm stearin oil, palmkernel olein oil, safflower oil, babassu oil, sweet almond oil, castoroil, canola oil, soybean oil, olive oil, acai oil, andiroba oil, apricotkernel oil, argan oil, passion fruit oil, manila oil, mango oil, sheaoil, macadamia nut oil, brazil nut oil, borage oil, copaiba oil, grapeseed oil, buriti oil, sesame oil, flaxseed oil, blueberry oil, cranberryoil, blackberry oil, plum oil, raspberry oil, camelina oil, camelliaoil, walnut oil, wheat germ oil, calendula oil, cherry kernel oil,cucumber seed oil, papaya oil, aloe vera oil, or mixtures orcombinations thereof.

In at least one example, the one or more plant oils includes flaxseedoil, hemp seed oil, or a combination of flaxseed oil and hemp seed oil.

In at least one example, the one or more plant oils may be present in anamount of from greater than 0 weight % to less than 40 weight %, about0.0001 weight % to about 10 weight %, or about 0.00025 weight % to about1 weight %, based on a total weight of the personal care composition.

In at least one example, the cannabinoid source may include one or morecannabinoids, optionally the one or more cannabinoids may include one ormore of cannabichromene, cannabichromevarin, cannabigerol,cannabigerovarin, cannabigerol monomethyl ether, cannabielsoin,cannabicitran, cannabidiol, cannabidiolic acid, cannabinol,cannabidivarin, cannabicyclol, cannabivarin, tetrahydrocannabivarin,Δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid, or combinationsthereof.

In at least one example, the cannabinoid source may include one or moreof the following: cannabichromene, cannabigerol, cannabidiol,cannabinol, or combinations thereof.

In at least one example, the cannabinoid source may be substantiallyfree, preferably, free of a psychoactive cannabinoid. For example, thecannabinoid source may be substantially free, preferably, free ofΔ9-tetrahydrocannabinol.

In at least one example, the cannabinoid source includes cannabidiol.

In at least one example, the cannabinoid source may be present in anamount of from greater than 0 weight % to less than 40 weight %, about0.0001 weight % to about 10 weight %, or about 0.00025 weight % to about1 weight %, based on a total weight of the personal care composition.

In at least one example, the cannabinoid source may include cannabissativa seed oil, hemp seed oil, or a combination thereof.

In at least one example, the one or more plant oils and the cannabinoidsource may be present in a ratio effective to treat, decrease, reduce,or prevent skin irritation and/or skin inflammation. In at least oneexample, the one or more plant oils and the cannabinoid source may bepresent in a ratio of from about 1:0.1 to about 1:3, more preferablyfrom about 1:0.25 to about 1:2.

In at least one example, the carrier is a solid carrier. In anotherexample, the carrier is a liquid carrier.

In at least one example, the personal care composition is a skin careproduct.

The foregoing and/or other aspects and utilities embodied in the presentdisclosure may be achieved by providing a method for preparing any oneor more of the personal care compositions disclosed herein. The methodmay include contacting the carrier, the one or more plant oils, and thecannabinoid source with one another.

The foregoing and/or other aspects and utilities embodied in the presentdisclosure may be achieved by providing a method for treating orreducing skin irritation or skin inflammation. The method may includecontacting the skin with any one or more of the personal carecompositions disclosed herein. The method may further include decreasingthe amount of IL-1αin or on the skin.

In at least one example, the method may further include determining thepresence of the skin irritation or the skin inflammation. In oneexample, determining the presence of the skin irritation or the skininflammation may include measuring an elevated amount of IL-1α in theskin relative to a population baseline IL-1α value or a previousindividual baseline IL-1α value.

The foregoing and/or other aspects and utilities embodied in the presentdisclosure may be achieved by providing any one or more of the personalcare compositions disclosed herein for use in treating or reducing skinirritation or skin inflammation.

Further areas of applicability of the present disclosure will becomeapparent from the detailed description provided hereinafter. It shouldbe understood that the detailed description and specific examples, whileindicating some typical aspects of the disclosure, are intended forpurposes of illustration only and are not intended to limit the scope ofthe disclosure.

DETAILED DESCRIPTION

The following description of various typical aspect(s) is merelyexemplary in nature and is in no way intended to limit the disclosure,its application, or uses.

As used throughout this disclosure, ranges are used as shorthand fordescribing each and every value that is within the range. It should beappreciated and understood that the description in a range format ismerely for convenience and brevity, and should not be construed as aninflexible limitation on the scope of any embodiments or implementationsdisclosed herein. Accordingly, the disclosed range should be construedto have specifically disclosed all the possible subranges as well asindividual numerical values within that range. As such, any value withinthe range may be selected as the terminus of the range. For example,description of a range such as from 1 to 5 should be considered to havespecifically disclosed subranges such as from 1.5 to 3, from 1 to 4.5,from 2 to 5, from 3.1 to 5, etc., as well as individual numbers withinthat range, for example, 1, 2, 3, 3.2, 4, 5, etc. This appliesregardless of the breadth of the range.

Unless otherwise specified, all percentages and amounts expressed hereinand elsewhere in the specification should be understood to refer topercentages by weight. The amounts given are based on the active weightof the material.

Additionally, all numerical values are “about” or “approximately” theindicated value, and take into account experimental error and variationsthat would be expected by a person having ordinary skill in the art. Itshould be appreciated that all numerical values and ranges disclosedherein are approximate values and ranges, whether “about” is used inconjunction therewith. It should also be appreciated that the term“about,” as used herein, in conjunction with a numeral refers to a valuethat may be ±0.01% (inclusive), ±0.1% (inclusive), ±0.5% (inclusive),±1% (inclusive) of that numeral, ±2% (inclusive) of that numeral, ±3%(inclusive) of that numeral, ±5% (inclusive) of that numeral, ±10%(inclusive) of that numeral, or ±15% (inclusive) of that numeral. Itshould further be appreciated that when a numerical range is disclosedherein, any numerical value falling within the range is alsospecifically disclosed.

As used herein, “free” or “substantially free” of a material may referto a composition, component, or phase where the material is present inan amount of less than 10.0 weight %, less than 5.0 weight %, less than3.0 weight %, less than 1.0 weight %, less than 0.1 weight %, less than0.05 weight %, less than 0.01 weight %, less than 0.005 weight %, orless than 0.0001 weight % based on a total weight of the composition,component, or phase.

All references cited herein are hereby incorporated by reference intheir entireties. In the event of a conflict in a definition in thepresent disclosure and that of a cited reference, the present disclosurecontrols.

The present inventors have surprisingly and unexpectedly discovered thatpersonal care compositions including a synergistic combination offlaxseed oil (FSO) and a cannabinoid source, such as cannabidiol (CBD),significantly decreased the measured amount of IL-1α, a marker for skininflammation and irritation, in skin. The surprising and unexpecteddecrease in IL-1α was demonstrated when FSO and CBD were present in aratio of from about 1:0.25 to about 1:2.

COMPOSITIONS

Compositions disclosed herein may be or include a personal care productor a personal care composition thereof. For example, compositionsdisclosed herein may be a personal care composition, a personal careproduct, or form a portion of the personal care composition or thepersonal care product. As used herein, the term or expression “personalcare composition” may refer to a composition for topical application toskin of mammals, especially humans. The personal care composition maygenerally be a leave-on personal care composition or rinse off personalcare composition, and may include any product applied to a human body.The personal care composition is preferably a leave-on personal carecomposition. The personal care composition may be in any suitable form.Illustrative forms of the personal care composition may be or include,but is not limited to, a liquid, a lotion, a cream, a foam, a scrub, agel, a soap bar, a toner, a substance or composition applied with animplement or via a face mask, or the like. Illustrative personal carecompositions may be or include, but are not limited to, cleansers,leave-on skin lotions or creams, emulsion, shampoos, conditioners,shower gels, antiperspirants, deodorants, depilatories, lipsticks,foundations, mascara, sunless tanners, sunscreen lotions, body washes,soaps, including bar soaps and liquid soaps (e.g., liquid hand soaps),face washes, moisturizers, serums, spot treatments, cosmetics, or thelike.

In an exemplary implementation, the compositions disclosed herein may beor include personal care compositions including a carrier, one or moreplant oils, and one or more cannabinoid sources. In one example, thepersonal care composition may include a single plant oil. In anotherexample, the personal care composition may include at least two plantoils. In yet another example, the personal care composition includes theone or more plant oils and the one or more cannabinoid sources in asynergistic amount or ratio (e.g., concentration, weight, or volumeratio). In at least one implementation, the personal care compositionincludes a synergistic amount or ratio of flaxseed oil (FSO) and acannabinoid source. For example, the personal care composition includesa synergistic amount or ratio of flaxseed oil (FSO) and the cannabinoidsource, where the cannabinoid source includes cannabidiol (CBD), andwhere the CBD may be a solution of CBD in hemp seed oil.

The personal care compositions disclosed herein may also be capable ofor configured to significantly decrease the measured amount of IL-1α, amarker for skin inflammation and irritation. As such, the personal carecomposition disclosed herein may be capable of or configured to treat,decrease, reduce, or otherwise prevent skin inflammation and/orirritation. For example, the personal care compositions disclosed hereinmay be capable of or configured to significantly decrease the measuredamount of IL-1α when the plant oil, such as FSO, and the cannabinoidsource are present in a synergistic amount or ratio, such as a ratio offrom about 4:1 (or about 1:0.25) to about 1:2. Accordingly, the personalcare compositions disclosed herein may be utilized in the treatmentand/or prevention of skin irritation or skin inflammation.

The personal care composition may include one or more plant oils. Forexample, the personal care composition may include a single plant oil ora combination of two or more plant oils. As used herein, “plant oil” mayrefer to a natural oil that is completely obtained from a plant, or amanufactured oil made by blending at least two components of oil (e.g.,triglycerides, saturated and/or unsaturated fatty acids, etc.) tosubstantially mimic the composition of a natural plant oil or provide anoil substantially similar in composition to a plant oil. For example, amanufactured oil substantially similar in composition to a plant oil mayinclude at least 50 weight %, at least 60 weight %, at least 70 weight%, at least 80 weight %, at least 90 weight %, at least 95 weight %, atleast 98 weight %, at least 99 weight %, at least 99.5 weight %, atleast 99.9 weight %, or 100 weight % of the components that arenaturally found in the plant oil that the manufactured oil is designedto substantially mimic.

Illustrative plant oils may be or include, but are not limited to, palmkernel oil, coconut oil, avocado oil, canola oil, corn oil, cottonseedoil, olive oil, palm oil, high-oleic sunflower oil, mid-oleic sunfloweroil, sunflower oil, palm stearin oil, palm kernel olein oil, saffloweroil, babassu oil, sweet almond oil, castor oil, canola oil, soybean oil,olive oil, acai oil, andiroba oil, apricot kernel oil, argan oil,passion fruit oil, manila oil, mango oil, shea oil, macadamia nut oil,brazil nut oil, borage oil, copaiba oil, grape seed oil, buriti oil,sesame oil, flaxseed oil or linseed oil, blueberry oil, cranberry oil,blackberry oil, plum oil, raspberry oil, camelina oil, camellia oil,walnut oil, wheat germ oil, calendula oil, cherry kernel oil, cucumberseed oil, papaya oil, aloe vera oil, hemp oil, hemp seed oil, or thelike, or mixtures or combinations thereof. In at least one particularimplementation, the one or more plant oils may include flaxseed oil(FSO). In another implementation, the one or more plant oils may includeFSO and hemp seed oil (HSO).

In at least one implementation, any one or more of the plant oils may bepresent in the personal care composition in an effective amount or atherapeutically effective amount. As used herein, the expression or term“effective amount of one or more plant oils” or the like may refer to anamount of one or more plant oils sufficient to interact or worksynergistically with the cannabinoid source to elicit a response (e.g.,biological, medical, etc.) of a tissue, system, animal, or human that isbeing sought. For example a plant oil, such as FSO, may be present inthe personal care composition in an effective amount to interact or worksynergistically with the cannabinoid source, such as CBD (e.g., CBD inHSO), to reduce skin irritation and/or skin inflammation.

The amount or concentration of any one or more of the plant oils presentin the personal care composition may vary widely. In at least oneimplementation, any one or more of the plant oils may be present in thepersonal care composition in an amount sufficient to deliver aneffective amount and/or ratio, as disclosed herein, of the one or moreplant oils to skin cells when applied to an outer surface of the skin orouter dermis. It should be appreciated that the amount or concentrationof the one or more plant oils present in the in the personal carecomposition may be relatively greater than the effective amount, aspenetration of the one or more plant oils from the outer dermis to theskin cells may be at least partially determined by varying factors, asis known by those having ordinary skill in the art.

In at least one implementation, the amount of any one or more of theplant oils (e.g., each or a combination) present in the personal carecomposition may be from greater than 0 weight % to less than or equal to40 weight %, based on a total weight of the personal care composition.For example, any one or more of the plant oils may be present in thepersonal care composition in an amount of from greater than 0 weight %,about 0.00025 weight %, about 0.0001 weight %, about 0.001 weight %,about 0.01 weight %, about 0.1 weight %, about 0.2 weight %, about 0.3weight %, about 0.4 weight %, about 0.5 weight %, about 0.6 weight %,about 0.7 weight %, about 0.8 weight %, about 0.9 weight %, about 1weight %, about 1.2 weight %, about 1.4 weight %, about 1.6 weight %,about 1.8 weight %, about 2 weight %, about 3 weight %, about 4 weight%, about 5 weight %, about 6 weight %, about 7 weight %, about 8 weight%, about 9 weight %, about 10 weight %, about 15 weight %, or about 20weight % to about 25 weight %, about 30 weight %, about 35 weight %,about 40 weight %, based on a total weight of the personal carecomposition. In another example, any one or more of the plant oils maybe present in the personal care composition in an amount of at least0.00001 wt %, at least 0.0001 weight %, at least 0.001 weight %, atleast 0.01 weight %, at least 0.1 weight %, at least 1.0 weight %, atleast 1.5 weight %, at least 2.0 weight %, at least 2.5 weight %, atleast 3.0 weight %, at least 3.5 weight %, at least 4.0 weight %, atleast 5 weight %, at least 10 weight %, at least 20 at least %, at least30 weight %, or more, based on a total weight of the personal carecomposition. In yet another example, any one or more of the plant oilsmay be present in the personal care composition in an amount of fromgreater than 0 weight % to less than 40 weight %, less than 35 weight %,less than 30 weight %, less than 25 weight %, less than 20 weight %,less than 15 weight %, less than 10 weight %, less than 9 weight %, lessthan 8 weight %, less than 7 weight %, less than 6 weight %, less than 5weight %, less than 4 weight %, less than 3 weight %, less than 2 weight%, less than 1 weight %, less than 0.1 weight %, less than 0.01 weight%, less than 0.001 weight %, less than 0.0001 weight %, less than0.00001 weight %, based on a total weight of the personal carecomposition. In yet another example, any one or more of the plant oilsmay be present in the personal care composition in an amount of fromgreater than 0 weight % to about 5 weight %, about 0.01 weight % toabout 5 weight %, about 0.1 weight % to about 4.9 weight %, about 0.2weight % to about 4.8 weight %, about 0.3 weight % to about 4.7 weight%, about 0.4 weight % to about 4.6 weight %, about 0.5 weight % to about4.5 weight %, about 0.6 weight % to about 4.4 weight %, about 0.7 weight% to about 4.3 weight %, about 0.8 weight % to about 4.2 weight %, about0.9 weight % to about 4.1 weight %, about 1 weight % to about 4 weight%, about 1.2 weight % to about 3.8 weight %, about 1.4 weight % to about3.6 weight %, about 1.6 weight % to about 3.4 weight %, about 1.8 weight% to about 3.2 weight %, about 2 weight % to about 3 weight %, about 2.2weight % to about 2.8 weight %, or about 2.4 weight % to about 2.6weight %, based on a total weight of the personal care composition.

The personal care composition may include one or more cannabinoidsources. The cannabinoid source may include one or more cannabinoids.Illustrative cannabinoid sources may be or include, but are not limitedto, cannabichromene (CBC), cannabichromevarin (CBCV), cannabigerol(CBG), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM),cannabielsoin (CBE), cannabicitran (CBT), cannabidiol (CBD),cannabidiolic acid (CBDA), cannabinol (CBN), cannabidivarin (CBDV),cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV),Δ9-tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), orthe like, or combinations thereof. In at least one implementation, thecannabinoid source may include a cannabinoid selected from CBC, CBG,CBD, CBN, or combinations thereof. In a particular implementation, thecannabinoid source includes at least CBD. For example, the cannabinoidsource may include, consists essentially of, or consists of CBD asrepresented by Formula (1).

The cannabinoid source may be or include a non-psychoactive cannabinoid.For example, the cannabinoid source may be free or substantially free ofany one or more psychoactive cannabinoids, such asΔ9-tetrahydrocannabinol (THC). For example, the cannabinoid source mayinclude less than or equal to about 0.3 weight % THC, less than or equalto about 0.2 weight % THC, less than or equal to about 0.1 weight % THC,less than or equal to about 0.05 weight % THC, or less than or equal toabout 0.01 weight % THC, based on a total weight of the composition orthe cannabinoid source thereof.

In at least one implementation, the cannabinoid source or thecannabinoids thereof may be present in the form of an oil. For example,the cannabinoid source may be an oil including one or more cannabinoids.In at least one example, the oil including the one or more cannabinoidsmay be or include a cannabis sativa seed oil, hemp seed oil, orcombinations thereof. In at least one implementation, the cannabinoidsource may include one or more cannabinoids and HSO or cannabis sativaseed oil (CSO). The HSO or the CSO may be a carrier for the one or morecannabinoids. For example, the one or more cannabinoids may be disposed,mixed, suspended, dispersed, dissolved, combined with, or otherwisecontacted with the HSO or the CSO.

In at least one implementation, the cannabinoid source may be present inthe personal care composition in an effective amount or atherapeutically effective amount. As used herein, the expression or term“effective amount of the cannabinoid source” or the like may refer to anamount of the cannabinoid source sufficient to interact or worksynergistically with the one or more plant oils to elicit a response(e.g., biological, medical, etc.) of a tissue, system, animal, or humanthat is being sought. For example the cannabinoid source, such as CBD(e.g., CBD in HSO), may be present in the personal care composition inan effective amount to interact or work synergistically with the one ormore plant oils, such as FSO, to reduce skin irritation and/orinflammation.

The amount or concentration of any one or more of the cannabinoidsources present in the personal care composition may vary widely. In atleast one implementation, any one or more of the cannabinoid sources orthe cannabinoids thereof may be present in the personal care compositionin an amount sufficient to deliver an effective amount and/or ratio, asdisclosed herein, of the cannabinoid source or the cannabinoids thereofto skin cells when applied to an outer surface of the skin or outerdermis. It should be appreciated that the amount or concentration of thecannabinoid source or the cannabinoids thereof present in the in thepersonal care composition may be relatively greater than the effectiveamount, as penetration of the cannabinoid source or the cannabinoidsthereof from the outer dermis to the skin cells may be at leastpartially determined by varying factors, as is known by those havingordinary skill in the art.

In at least one implementation, the amount of the cannabinoid source orthe one or more cannabinoids thereof (e.g., each or a combination)present in the personal care composition may be from greater than 0weight % to less than or equal to 40 weight %, based on a total weightof the personal care composition. For example, the cannabinoid source orthe one or more cannabinoids thereof may be present in the personal carecomposition in an amount of from greater than 0 weight %, about 0.0001weight %, about 0.00025 weight %, about 0.001 weight %, about 0.01weight %, about 0.1 weight %, about 0.2 weight %, about 0.3 weight %,about 0.4 weight %, about 0.5 weight %, about 0.6 weight %, about 0.7weight %, about 0.8 weight %, about 0.9 weight %, about 1 weight %,about 1.2 weight %, about 1.4 weight %, about 1.6 weight %, about 1.8weight %, about 2 weight %, about 3 weight %, about 4 weight %, about 5weight %, about 6 weight %, about 7 weight %, about 8 weight %, about 9weight %, about 10 weight %, about 15 weight %, or about 20 weight % toabout 25 weight %, about 30 weight %, about 35 weight %, about 40 weight%, based on a total weight of the personal care composition. In anotherexample, the cannabinoid source or the one or more cannabinoids thereofmay be present in the personal care composition in an amount of at least0.00001 wt %, at least 0.0001 weight %, at least 0.001 weight %, atleast 0.01 weight %, at least 0.1 weight %, at least 1.0 weight %, atleast 1.5 weight %, at least 2.0 weight %, at least 2.5 weight %, atleast 3.0 weight %, at least 3.5 weight %, at least 4.0 weight %, atleast 5 weight %, at least 10 weight %, at least 20 at least %, at least30 weight %, or more, based on a total weight of the personal carecomposition. In yet another example, the cannabinoid source or the oneor more cannabinoids thereof may be present in the personal carecomposition in an amount of from greater than 0 weight % to less than 40weight %, less than 35 weight %, less than 30 weight %, less than 25weight %, less than 20 weight %, less than 15 weight %, less than 10weight %, less than 9 weight %, less than 8 weight %, less than 7 weight%, less than 6 weight %, less than 5 weight %, less than 4 weight %,less than 3 weight %, less than 2 weight %, less than 1 weight %, lessthan 0.1 weight %, less than 0.01 weight %, less than 0.001 weight %,less than 0.0001 weight %, less than 0.00001 weight %, based on a totalweight of the personal care composition. In yet another example, thecannabinoid source or the one or more cannabinoids thereof may bepresent in the personal care composition in an amount of from greaterthan 0 weight % to about 5 weight %, about 0.01 weight % to about 5weight %, about 0.1 weight % to about 4.9 weight %, about 0.2 weight %to about 4.8 weight %, about 0.3 weight % to about 4.7 weight %, about0.4 weight % to about 4.6 weight %, about 0.5 weight % to about 4.5weight %, about 0.6 weight % to about 4.4 weight %, about 0.7 weight %to about 4.3 weight %, about 0.8 weight % to about 4.2 weight %, about0.9 weight % to about 4.1 weight %, about 1 weight % to about 4 weight%, about 1.2 weight % to about 3.8 weight %, about 1.4 weight % to about3.6 weight %, about 1.6 weight % to about 3.4 weight %, about 1.8 weight% to about 3.2 weight %, about 2 weight % to about 3 weight %, about 2.2weight % to about 2.8 weight %, or about 2.4 weight % to about 2.6weight %, based on a total weight of the personal care composition.

As discussed above, the personal care composition may include asynergistic amount and/or combination of the one or more plant oils andthe cannabinoid sources, or the one or more cannabinoids thereof. Forexample, the personal care composition may include a synergisticcombination of the one or more plant oils and the cannabinoid source.

In at least one implementation, the one or more plant oils and thecannabinoid source may be present in an effective ratio (i.e.,concentration, weight, or volume ratio) or a therapeutically effectiveratio (i.e., concentration, weight, or volume ratio) to elicit aresponse (e.g., biological medical, etc.) of a tissue, system, animal,or human that is being sought. For example, the one or more plant oils,such as FSO, and the cannabinoid source or the one or more cannabinoidsthereof, such as CBD, may be present in an effective concentration,weight, or volume ratio or a therapeutically effective concentration,weight, or volume ratio to treat, decrease, reduce, or otherwise preventskin irritation and/or inflammation.

In at least one implementation, the concentration, weight, or volumeratio of the one or more plant oils to the cannabinoid source or the oneor more cannabinoids thereof may be from about 1:0.1 to about 1:5. Forexample, the concentration, weight, or volume ratio of the plant oil tothe cannabinoid source may be about 1:0.1, about 1:0.15, about 1:0.2,about 1:0.25, about 1:0.3, about 1:0.35, about 1:0.4, about 1:0.45,about 1:0.5, about 1:0.55, about 1:0.6, about 1:0.65, about 1:0.7, about1:0.75, about 1:0.8, about 1:0.85, about 1:0.9, about 1:0.95, about 1:1,about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about1:1.6, about 1:1.7, about 1:1.8, about 1:1.9, about 1:2, about 1:2.1,about 1:2.2, about 1:2.3, about 1:2.4, about 1:2.5, about 1:2.6, about1:2.7, about 1:2.8, about 1:2.9, about 1:3, about 1:3.1, about 1:3.2,about 1:3.3, about 1:3.4, about 1:3.5, about 1:3.6, about 1:3.7, about1:3.8, about 1:3.9, about 1:4, about 1:4.1, about 1:4.2, about 1:4.3,about 1:4.4, about 1:4.5, about 1:4.6, about 1:4.7, about 1:4.8, about1:4.9, or about 1:5. In another example, the concentration, weight, orvolume ratio of the plant oil to the cannabinoid source may be fromgreater than or equal to about 1:0.1 and less than or equal to about1:5, less than or equal to about 1:4, less than or equal to about 1:3,less than or equal to about 1:2.8, less than or equal to about 1:2.6,less than or equal to about 1:2.4, less than or equal to about 1:2.3,less than or equal to about 1:2.2, less than or equal to about 1:2, lessthan or equal to about 1:1.8, less than or equal to about 1:1.6, lessthan or equal to about 1:1.4, less than or equal to about 1:1.2, lessthan or equal to about 1:1, less than or equal to about 1:0.8, less thanor equal to about 1:0.7, less than or equal to about 1:0.6, less than orequal to about 1:0.5, less than or equal to about 1:0.45, less than orequal to about 1:0.4, less than or equal to about 1:0.35, less than orequal to about 1:0.3, less than or equal to about 1:0.25, less than orequal to about 1:0.2, or less than or equal to about 1:0.15. In yetanother example, the concentration, weight, or volume ratio of the plantoil to the cannabinoid source may be from greater than or equal to about1:0.1, greater than or equal to about 1:0.15, greater than or equal toabout 1:0.2, greater than or equal to about 1:0.25, greater than orequal to about 1:0.3, greater than or equal to about 1:0.35, greaterthan or equal to about 1:0.4, a greater than or equal to bout 1:0.45,greater than or equal to about 1:0.5, greater than or equal to about1:0.55, greater than or equal to about 1:0.6, greater than or equal toabout 1:0.65, greater than or equal to about 1:0.7, greater than orequal to about 1:0.75, greater than or equal to about 1:0.8, greaterthan or equal to about 1:0.85, greater than or equal to about 1:0.9,greater than or equal to about 1:0.95, greater than or equal to about1:1, greater than or equal to about 1:1.1, greater than or equal toabout 1:1.2, greater than or equal to about 1:1.3, greater than or equalto about 1:1.4, greater than or equal to about 1:1.5, greater than orequal to about 1:1.6, greater than or equal to about 1:1.7, greater thanor equal to about 1:1.8, greater than or equal to about 1:1.9, greaterthan or equal to about 1:2, greater than or equal to about 1:2.1,greater than or equal to about 1:2.2, greater than or equal to about1:2.3, greater than or equal to about 1:2.4, greater than or equal toabout 1:2.5, greater than or equal to about 1:2.6, greater than or equalto about 1:2.7, greater than or equal to about 1:2.8, greater than orequal to about 1:2.9, greater than or equal to about 1:3, greater thanor equal to about 1:3.1, greater than or equal to about 1:3.2, greaterthan or equal to about 1:3.3, greater than or equal to about 1:3.4,greater than or equal to about 1:3.5, greater than or equal to about1:3.6, greater than or equal to about 1:3.7, greater than or equal toabout 1:3.8, greater than or equal to about 1:3.9, greater than or equalto about 1:4, greater than or equal to about 1:4.1, greater than orequal to about 1:4.2, greater than or equal to about 1:4.3, greater thanor equal to about 1:4.4, greater than or equal to about 1:4.5, greaterthan or equal to about 1:4.6, greater than or equal to about 1:4.7,greater than or equal to about 1:4.8, or greater than or equal to about1:4.9 to less than or equal to about 1:5. In a particularimplementation, the concentration, weight, or volume ratio of the plantoil, such as FSO, to the cannabinoid source, such as CBD in HSO, may befrom about 1:0.1 to about 1:3, more preferably from about 1:0.25 toabout 1:2. For example, the concentration, weight, or volume ratio offlaxseed oil to a 1% solution of CBD in HSO may be from about 1:0.1 toabout 1:3, more preferably from about 1:0.25 to about 1:2.

The personal care composition may include the active ingredients, mixedwith, dissolved in, combined with, or otherwise contacted with thecarrier or one or more excipients. For example, the personal carecomposition may include the one or more plant oils and the cannabinoidsource or the one or more cannabinoids thereof mixed with, dissolved in,combined with, or otherwise contacted with the carrier or one or moreexcipients. In at least one implementation, the carrier may be capableof or configured to store, entrain, or otherwise contain the one or moreplant oils and the cannabinoid source or the one or more cannabinoidsthereof, and deliver the one or more plant oils and the cannabinoidsource or the one or more cannabinoids thereof to one or more tissues,such as skin. It should be appreciated that the components or contentsof the carrier and the respective amount of each of the components ofthe carrier may be at least partially determined by the type or use ofthe personal care product or the composition thereof. Illustrativepersonal care products or compositions thereof may include, but are notlimited to, cleansers, leave-on skin lotions or creams, emulsion,shampoos, conditioners, shower gels, antiperspirants, deodorants,depilatories, lipsticks, foundations, mascara, sunless tanners,sunscreen lotions, body washes, soaps, including bar soaps and liquidsoaps (e.g., liquid hand soaps), face washes, moisturizers, serums, spottreatments, cosmetics, or the like. In a preferred implementation, thepersonal care product or the composition thereof that includes the oneor more plant oils and the cannabinoid source or the one or morecannabinoids thereof are solid cleansing compositions, such as barsoaps.

In at least one implementation, the personal care product or thecomposition thereof may be a skin care product. Illustrative skin careproduct may be or include, but are not limited to, a lotion, a cosmetic,a sunscreen, or the like. The carrier of the skin care product mayinclude, but is not limited to, any one or more of surfactants,conditioning agents, moisturizers, sunscreens, UV absorbers,antioxidants, enzymes and/or other proteins, vitamins, antibacterialagents, odor reducing agents, steroids, anti-inflammatory agents,naturally and/or non-naturally occurring humectants, skin lipidfluidizers, occlusive agents, amino acids, physical and/or chemicalexfoliants, skin whiteners, anti-aging, antiperspirant actives, or thelike, or any combination thereof.

In at least one implementation, the personal care product or thecomposition thereof may be a personal hand and/or body cleansingcomposition or a personal hand and/or body conditioning composition.Illustrative personal hand and/or body cleansing or conditioningcompositions may include, but are not limited to, liquid soaps, barsoaps, body washes, shower gels, lotions, and the like. In a preferredimplementation, the personal hand and/or body cleansing or conditioningcomposition is a solid personal hand and/or solid body cleansing orconditioning composition, such as bar soap. The carrier for the personalhand and/or body cleansing composition or the personal hand and/or bodyconditioning composition may include, but is not limited to, any one ormore of fragrances, essential oils, emulsifying agents, thickeningagents, colorants, surfactants, natural actives, therapeutic actives,stain prevention actives, antimicrobial agents, vitamins, naturalextracts, amino acids, enzymes and/or other proteins, abrasives, odorcontrol agents, conditioning agents, moisturizers, humectants, occlusiveagents, skin lipid fluidizers, lipophilic actives, hydrophilicmaterials, pearlizers, opacifying agents, sodium soaps, titaniumdioxide, fragrances, or the like, or any mixture or combination thereof,in addition to any one or more of the other carrier components asdiscussed above.

The carrier may be hydrophilic or hydrophobic. The carrier may beanhydrous. The carrier may be a liquid or a solid at room temperature.The carrier may have a viscosity of from about 2,000 centipoise (cP) toabout 100,000 cP. For example, the carrier for a shower gel may have aviscosity of from about 2,000 cP to about 16,000 cP. In another example,the carrier for a lotion may have a viscosity of from about 10,000 cP toabout 100,000 cP. Accordingly, it should be appreciated that theviscosity of the carrier may vary and may at least partially depend onthe type of personal care composition. In an exemplary implementation,the carrier is a solid at room temperature.

Unless otherwise specifically identified, the ingredients for use in thecompositions and formulations of the compositions disclosed herein arepreferably cosmetically acceptable ingredients. As used herein, theexpression “cosmetically acceptable” may refer to a component oringredient that is suitable for use in a formulation for topicalapplication to human skin. A cosmetically acceptable excipient, mayrefer to an excipient that is suitable for external application in theamounts and concentrations contemplated in the formulations of thecompositions disclosed herein, and includes for example, excipientswhich are “Generally Recognized as Safe” (GRAS) by the United StatesFood and Drug Administration (FDA).

METHODS

The present disclosure may provide methods for preparing a personal careproduct or a personal care composition thereof. The method may includemixing, stirring, combining, or otherwise contacting the one or moreplant oils and the one or more cannabinoid sources with a carrier. In atleast one example, the carrier may be a solid cleansing composition,such as a bar soap.

The present disclosure may further provide methods for treating orreducing one or more skin conditions, such as skin irritation or skininflammation. Illustrative irritation or inflammatory conditions may beor include, but are not limited to, redness, itchiness, pruritus,pyoderma, dermal rashes, chaffing, or the like, or combinations thereof.The method for treating or reducing one or more skin conditions mayinclude contacting an effective amount of any one or more of thepersonal care compositions disclosed herein with the skin. The methodmay also include decreasing the amount of IL-1α in and/or on the skin bycontacting the effective amount of any one or more of the personal carecompositions disclosed with the skin. The method may also includediagnosing or determining the presence of skin irritation and/or skininflammation. The method for diagnosing or determining the presence ofskin irritation and/or skin inflammation may include measuring anelevated amount of IL-1α relative to a population baseline value or aprevious individual baseline value. The elevated amount of IL-1α may beat least 1% greater, at least 2% greater, at least 5% greater, at least8% greater, at least 10% greater, at least 12% greater, at least 15%greater, at least 20% greater, at least 25% greater, at least 30%greater, at least 40% greater, at least 50% greater, at least 60%greater, at least 70% greater, at least 80% greater, at least 90%greater, at least 100% greater, at least 150% greater, at least 200%greater, at least 250% greater, at least 300% greater, at least 400%greater, or at least 500% greater, than the population baseline value orthe previous individual baseline value.

The present disclosure may also provide a personal care compositionincluding a carrier, one or more plant oils, and a cannabinoid sourcefor use in treating one or more skin conditions, such as skin irritationand/or skin inflammation. The one or more plant oils may include FSO.The cannabinoid source may include one or more cannabinoids. The one ormore cannabinoids of the cannabinoid source may include CBD. The CBD maybe a 1% solution of CBD in HSO.

EXAMPLES

The examples and other implementations described herein are exemplaryand not intended to be limiting in describing the full scope ofcompositions and methods of this disclosure. Equivalent changes,modifications and variations of specific implementations, materials,compositions and methods may be made within the scope of the presentdisclosure, with substantially similar results.

Example

An in vitro study was conducted to determine the efficacy of varyingconcentrations of flaxseed oil (FSO) and cannabidiol (CBD) in hemp seedoil (HSO) for preventing, reducing, and/or treating skin irritation.Particularly, an in vitro study was conducted on keratinocyte cell skinmodels to determine the effect or efficacy of varying concentrations ofFSO and CBD in HSO in reducing Interleukin 1 alpha (IL-1α). It should beappreciated that IL-1α, or hematopoietin 1, is a cytokine of theinterleukin 1 family that is encoded by the IL-1α gene. It shouldfurther be appreciated that Interleukin 1 is responsible for theproduction of inflammation and/or irritation of the skin, and has beenwidely used as a marker or biomarker to evaluate skin irritation.

Stock solutions of FSO and CBD in HSO were prepared. A 100% FSO and a 1%solution of CBD in HSO were utilized to prepare the stock solutions. The100% FSO was combined with 100% dimethyl sulfoxide (DMSO) in a ratio ofabout 1:99 to thereby prepare a solution of FSO in DMSO. Similarly, the1% solution of CBD in HSO was combined with 100% DMSO in a ratio ofabout 1:99 to thereby prepare a solution of CBD. 100 μL of each of thesolutions of FSO in DMSO and CBD in DMSO was then combined with 900 μLphosphate-buffered saline (PBS) to prepare respective stock solutions ofFSO and CBD. A stock 10% DMSO solution was prepared by combining 100 μLof DMSO with 900 μL of PBS.

The stock solutions were utilized to prepare eight separate samples(1)-(8) including varying amounts of FSO, CBD, and growth media. Theamounts or concentrations of each of the samples (1)-(8) are summarizedin Table 1. A brief description of each of the samples (1)-(8) issummarized in Table 2.

TABLE 1 Composition of Samples (1)-(8) 1 2 3 4 5 6 7 8 Ingredient mL mLmL mL mL mL mL mL FSO 0 0.1 0 0 0 0.1 0.1 0.1 (0.1% soln) CBD 0 0 0.20.1 0.025 0.2 0.1 0.025 (0.1% soln) Media 9.8 9.9 9.8 9.9 9.975 9.7 9.89.875 DMSO 0.2 0 0 0 0 0 0 0

TABLE 2 Brief Description of Samples (1)-(8) Sample Brief Description 1Vehicle Control 2 0.001% FSO 3 0.002% CBD 4 0.001% CBD 5 0.00025% CBD 60.001% FSO + 0.002% CBD 7 0.001% FSO + 0.001% CBD 8 0.001% FSO +0.00025% CBD

Keratinocyte cell skin models were utilized as the models in the invitro study, and IL-1αwas monitored with an IL-1α ELISA Kit. To conductthe in vitro study, Keratinocyte cell were grown in a 6-well plate toreach the confluency of about >60%. About 2 mL of each of the samples(1)-(8) was directly applied to respective wells of the well plate andincubated for 24 hours. After incubation, the cells from each of thewells were collected and used as is. The amount of IL-1α produced inskin models treated with the respective samples (1)-(8) is summarized inTable 3. All measurements were done in triplicate, averaged, andnormalized to the total protein in each of the keratinocyte cell skinmodels.

TABLE 3 Amount of IL-1α Measured from Skin Models Treated with Samples(1)-(8) Amount of IL-1α Change from # Sample (Pg/mL) Control 1 Control12.7 0 2 0.001% FSO 15.2 2.5 3 0.002% CBD 8.9 −3.8 4 0.001% CBD 6.8 −5.95 0.00025% CBD 5.8 −6.9 6 0.001% FSO + 0.002% CBD 4.0 −8.7 7 0.001%FSO + 0.001% CBD 5.1 −7.6 8 0.001% FSO + 0.00025% CBD 5.2 −7.5

Based on the changes relative to control for samples (2) to (5),respectively, it was expected that the amount of IL-1α in samples (6),(7), and (8) would be a decrease of about −1.3 Pg/mL, about −3.4 Pg/mL,and about −4.4 Pg/mL, respectively. It was surprising and unexpectedlydiscovered, however, that the combination of FSO and CBD resulted in asignificant decrease of about −8.7 Pg/mL, −7.6 Pg/mL, and −7.5 Pg/mL,respectively. The results are especially surprising as the presence ofFSO alone, as in sample (1), resulted in an increase in the amount ofIL-1α relative to the control. Accordingly, an increase relative to thecontrol would be expected as opposed to the observed decrease whencombining FSO with CBD. The results suggest that providing a ratio ofFSO to CBD of from about 4:1 (about 1:0.25) to about 1:2 surprisinglyand unexpectedly decreased the production of IL-1α in skin. As such,providing a ratio of FSO to CBD of from about 4:1 (about 1:0.25) toabout 1:2 would surprisingly and unexpectedly decrease, treat, and/orreduce skin irritation.

The present disclosure has been described with reference to exemplaryimplementations. Although a limited number of implementations have beenshown and described, it will be appreciated by those skilled in the artthat changes may be made in these implementations without departing fromthe principles and spirit of the preceding detailed description. It isintended that the present disclosure be construed as including all suchmodifications and alterations insofar as they come within the scope ofthe appended claims or the equivalents thereof.

1. A personal care composition, comprising a carrier, one or more plantoils, and a cannabinoid source, wherein the one or more plant oils andthe cannabinoid source are each present in an effective amount to treator reduce skin irritation or skin inflammation.
 2. The personal carecomposition of claim 1, wherein the one or more plant oils comprise oneor more of palm kernel oil, coconut oil, avocado oil, canola oil, cornoil, cottonseed oil, olive oil, palm oil, high-oleic sunflower oil,mid-oleic sunflower oil, sunflower oil, palm stearin oil, palm kernelolein oil, safflower oil, babassu oil, sweet almond oil, castor oil,canola oil, soybean oil, olive oil, acai oil, andiroba oil, apricotkernel oil, argan oil, passion fruit oil, manila oil, mango oil, sheaoil, macadamia nut oil, brazil nut oil, borage oil, copaiba oil, grapeseed oil, buriti oil, sesame oil, flaxseed oil, blueberry oil, cranberryoil, blackberry oil, plum oil, raspberry oil, camelina oil, camelliaoil, walnut oil, wheat germ oil, calendula oil, cherry kernel oil,cucumber seed oil, papaya oil, aloe vera oil, or mixtures orcombinations thereof.
 3. The personal care composition of claim 1,wherein the one or more plant oils comprise flaxseed oil, hemp seed oil,or a combination of flaxseed oil and hemp seed oil.
 4. The personal carecomposition of claim 1, wherein the one or more plant oils are presentin an amount of from greater than 0 weight % to less than 40 weight %,about 0.0001 weight % to about 10 weight %, or about 0.00025 weight % toabout 1 weight %, based on a total weight of the personal carecomposition.
 5. The personal care composition of claim 1, wherein thecannabinoid source comprises one or more cannabinoids, optionally theone or more cannabinoids comprises one or more of cannabichromene,cannabichromevarin, cannabigerol, cannabigerovarin, cannabigerolmonomethyl ether, cannabielsoin, cannabicitran, cannabidiol,cannabidiolic acid, cannabinol, cannabidivarin, cannabicyclol,cannabivarin, tetrahydrocannabivarin, Δ9-tetrahydrocannabinol,tetrahydrocannabinolic acid, or combinations thereof.
 6. The personalcare composition of claim 1, wherein the cannabinoid source comprisesone or more of cannabichromene, cannabigerol, cannabidiol, cannabinol,or combinations thereof.
 7. The personal care composition of claim 1,wherein the cannabinoid source is substantially free, preferably, freeof a psychoactive cannabinoid.
 8. The personal care composition of claim1, wherein the cannabinoid source is substantially free, preferably,free of Δ9-tetrahydrocannabinol.
 9. The personal care composition ofclaim 1, wherein the cannabinoid source comprises cannabidiol.
 10. Thepersonal care composition of claim 1, wherein the cannabinoid source ispresent in an amount of from greater than 0 weight % to less than 40weight %, about 0.0001 weight % to about 10 weight %, or about 0.00025weight % to about 1 weight %, based on a total weight of the personalcare composition.
 11. The personal care composition of claim 1, whereinthe cannabinoid source comprises cannabis sativa seed oil, hemp seedoil, or a combination thereof.
 12. The personal care composition ofclaim 1, wherein the one or more plant oils and the cannabinoid sourceare present in a ratio effective to treat, decrease, reduce, or preventskin irritation and/or skin inflammation.
 13. The personal carecomposition of claim 1, wherein the one or more plant oils and thecannabinoid source are present in a ratio of from about 1:0.1 to about1:3, more preferably from about 1:0.25 to about 1:2.
 14. The personalcare composition of claim 1, wherein the carrier is a solid carrier. 15.The personal care composition of claim 1, wherein the carrier is aliquid carrier.
 16. The personal care composition of claim 1, whereinthe personal care composition is a skin care product.
 17. A method forpreparing the personal care composition of claim 1, the methodcomprising contacting the carrier, the one or more plant oils, and thecannabinoid source with one another.
 18. A method for treating orreducing skin irritation or skin inflammation, the method comprisingcontacting the skin with the personal care composition of claim 1,optionally, the method further comprising decreasing the amount of IL-1αin or on the skin.
 19. The method of claim 18, further comprisingdetermining the presence of the skin irritation or the skininflammation, optionally, wherein determining the presence of the skinirritation or the skin inflammation comprises measuring an elevatedamount of IL-1α in the skin relative to a population baseline IL-1αvalue or a previous individual baseline IL-1α value.
 20. The personalcare composition of claim 1 for use in treating or reducing skinirritation or skin inflammation.